AASLD 2015

Predictors of Response with Grazoprevir/Elbasvir in HCV GT1a

Among patients with treatment-naïve genotype 1a (GT1a) hepatitis C virus (HCV) infection treated with grazoprevir/elbasvir with or without ribavirin, baseline HCV RNA level and baseline NS5A resistance-associated variants (RAVs) conferring a greater than 5-fold shift in potency of elbasvir in vitro were identified as significant predictors of sustained virologic response 12 weeks after end of therapy (SVR12), a study concluded at The Liver Meeting® 2015.

Which HCV Regimens Report Higher Adherence Levels?

Non-adherence to antiviral regimens may be predicted by the use of pegylated interferon, ribavirin, duration of treatment, and lower baseline and on-treatment patient-reported outcomes (PRO) scores, reported Zobair Younossi, MD, MPH, from Inova Fairfax Hospital, Falls Church, VA, at The Liver Meeting® 2015.

Nucleos(t)ide Analogs Lower HCC Recurrence Risk in HBV Patients

Nucleos(t)ide analog (NA) treatment reduces the risk of hepatocellular carcinoma (HCC) recurrence and possibly death in patients with chronic hepatitis B virus (HBV) infection, particularly among those who received tumor resection and local ablative treatment for HCC, according to research presented at The Liver Meeting® 2015.